Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in xenotransplantation.

M S Sandrin1, I F McKenzie

  • 1Molecular Immunogenetics Laboratory, Austin Research Institute, Austin and Repatriation Medical Centre, Studley Road, Heidelberg, Victoria, 3084, Australia. m.sandrin@ari.unimelb.edu.au

Current Opinion in Immunology
|October 6, 1999
PubMed
Summary

Pig-to-human xenotransplantation faces hyperacute rejection due to anti-Galalpha(1,3)Gal antibodies. New strategies focus on reducing Galalpha(1,3)Gal expression or complement activation to improve transplant success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fucosyl transferase (H) transgenic heart transplants to Gal-/- mice.

Transplantation·2000
Same author

Human monocytes bind to ligands on porcine endothelium containing the gal alpha (1,3)-Gal antigen.

Transplantation proceedings·2000
Same author

Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.

Vaccine·2000
Same author

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.

European journal of immunology·2000
Same author

A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo.

European journal of immunology·2000
Same author

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaccine·2000

Area of Science:

  • Xenotransplantation research
  • Immunology
  • Transgenic technology

Background:

  • The primary obstacle in pig-to-human xenotransplantation is hyperacute rejection.
  • This rejection is mediated by host anti-Galalpha(1,3)Gal antibodies and complement activation.
  • Galalpha(1,3)Gal also plays a role in other forms of xenograft rejection involving immune cells.

Purpose of the Study:

  • To review strategies for overcoming hyperacute rejection in xenotransplantation.
  • To highlight the role of Galalpha(1,3)Gal in various rejection pathways.
  • To discuss the progress of transgenic approaches in clinical trials.

Main Methods:

  • Review of existing literature on xenotransplantation rejection mechanisms.
  • Analysis of transgenic strategies to modify Galalpha(1,3)Gal expression.

Related Experiment Videos

  • Examination of complement inhibition techniques.

    • Main Results:

    • Transgenic approaches to eliminate or reduce Galalpha(1,3)Gal are being tested in primate trials.
    • These strategies aim to prevent antibody- and complement-dependent hyperacute rejection.
    • Emerging evidence points to Galalpha(1,3)Gal's involvement in natural killer cell and monocyte-mediated rejection.

    Conclusions:

    • Overcoming Galalpha(1,3)Gal-mediated rejection is critical for successful xenotransplantation.
    • Transgenic modifications and complement reduction are promising strategies.
    • Further research is needed to address Galalpha(1,3)Gal's role in antibody-independent rejection pathways.